Scientists at Tata Memorial Centre in India have discovered that a short-term therapy of three to six months is as effective as the traditional year-long treatment for early-stage HER2-positive breast cancer, with fewer cardiac side effects. The study, which included a meta-analysis of data from multiple clinical trials, suggests that the drug Trastuzumab (brand name Herceptin) can be administered for a shorter period without compromising disease-free survival. This finding could significantly reduce the cost and emotional strain of prolonged treatment for patients. The study was published in the Journal of the American Medical Association and highlights the potential for reduced cardiac toxicity and healthcare expenses. Breast cancer is the most common cancer in women worldwide, with HER2-positive cases making up a significant portion. The high cost of Trastuzumab is a concern, and a shorter treatment duration could alleviate financial burdens for patients.